MEK/CDK4,6 co-targeting is effective in a subset of NRAS, BRAF and ‘wild type’ melanomas

Targeted therapy has become a cornerstone for the treatment of melanoma patients. Targeting NRAS function is particularly challenging. To date, only single MEK inhibitor treatment was able to show minimal clinical efficacy. The discovery that co-targeting of MEK and CDK4,6 has antitumor activity cre...

Descripción completa

Detalles Bibliográficos
Autores principales: Posch, Christian, Sanlorenzo, Martina, Ma, Jeffrey, Kim, Sarasa T., Zekhtser, Mitchell, Ortiz-Urda, Susana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201855/
https://www.ncbi.nlm.nih.gov/pubmed/30405888
http://dx.doi.org/10.18632/oncotarget.26204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6201855/
https://www.ncbi.nlm.nih.gov/pubmed/30405888
http://dx.doi.org/10.18632/oncotarget.26204

Ejemplares similares